Cardiology Pharmaceuticals
November 16, 2026
What We Learn When Big Hypotheses Fail November 16, 2026
We’ve known for months now that neither Novo’s ZEUS trial nor Novartis’ Lp(a)HORIZON yielded positive topline results for their respective drugs and while the full data at AHA 2026 wasn’t a win for these pharma giants, it’s certain to help shape cardiac science.
Cardiology Pharmaceuticals
November 12, 2026
The First Ever Factor XIa Gets Approved for Secondary Stroke November 12, 2026
Adding anticoagulants to antiplatelet therapy after stroke has always meant trading clots for bleeds, but that’s changing thanks to Bayer’s asundexian (Sunharbo), which just became the first-ever FDA-approved Factor XIa inhibitor for secondary stroke prevention.
Structural Heart
November 9, 2026
Can TAVR Make PROGRESS Against Moderate AS? November 9, 2026
To TAVR or not to TAVR, that is the question central to the PROGRESS trial presented at TCT 2026, and its results suggest the answer might be the former for certain high-risk patients with moderate AS.